BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Innovations | May 22, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Addiction Metabotropic glutamate receptor subtype 2 (mGluR2; GRM2); mGluR3 (GRM3) In vitro and rat studies suggest positive allosteric modulators (PAMs) of both mGluR2 and mGluR3...
BioCentury | Apr 7, 2014

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
BC Week In Review | Feb 10, 2014
Clinical News

ADX71149: Phase IIa data

Addex said top-line data from a double-blind, international Phase IIa trial evaluating twice-daily oral ADX71149 for 8 weeks as an adjunct to a selective serotonin reuptake inhibitor (SSRI) or a serotonin/norepinephrine reuptake inhibitor (SNRI) in...
BC Extra | Feb 8, 2014
Clinical News

ADX71149 misses in Phase IIa for anxious depression

Addex Therapeutics Ltd. (SIX:ADXN) said top-line data from a Phase IIa trial evaluating ADX71149 to treat major depressive disorder (MDD) with anxiety symptoms do not support further development of the compound for anxious depression. In...
BC Week In Review | Nov 4, 2013
Clinical News

ADX71149: Completed Phase II enrollment

Addex said Johnson & Johnson's Janssen Pharmaceuticals Inc. unit completed enrollment of 120 MDD patients with anxiety symptoms in a double-blind, placebo-controlled, international Phase IIa trial evaluating 25-150 mg oral ADX71149 twice daily for 8...
BC Innovations | Oct 24, 2013

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
BC Extra | Aug 9, 2013
Financial News

Addex raises CHF3.2 million

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF3.2 million ($3.5 million) through the sale of 1.2 million shares at CHF2.75 in a private placement to existing investors including BVF Partners and new investors Armistice Capital and EcoR1...
BC Week In Review | Jun 3, 2013
Company News

Addex neurology news

Addex reduced headcount by 17 (89%) to 2 to conserve cash while pursuing a 2004 deal with the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Bharatt Chowrira has stepped down...
BC Week In Review | Nov 19, 2012
Clinical News

ADX71149: Phase IIa data

Addex reported top-line data from the double-blind, placebo-controlled Part B portion of a European Phase IIa trial in 92 patients receiving stable doses of antipsychotics showing that twice-daily 50 and 150 mg ADX71149 "met the...
Items per page:
1 - 10 of 22